0001140361-26-019630
SEC filingQ1 revenue declined 12.0% to $320.6M amid tough prior-year comparisons, tariff-related order delays, and economic uncertainty, squeezing profitability despite gross margin stability at 66.9% and operating income swing to $4.0M profit.
Revenue of $320.6 million decreased 12.0% from $364.5 million in Q1 2025, primarily due to a tough comparison with a strong prior-year quarter combined with customer order delays linked to tariff and economic uncertainty. This decline impacted segment contributions across regions, as management notes the year-over-year drop reflects lower sales volumes alongside fixed cost pressures in cost of goods sold and slight G&A increases from pre-market activities in India ahead of its full opening in late 2026.
Gross profit declined 13.2% to $214.5 million, yielding a stable 66.9% margin versus prior year. The margin resilience amid revenue contraction stems from controlled variable costs, though fixed COGS elements exerted pressure. Operating income swung to a $4.0 million profit (1.3% margin) from a $9.9 million loss, driven by the revenue shortfall offset by favorable expense leverage in some areas. Management attributes segment contribution decreases to revenue declines plus G&A tied to India preparations and other general expense increases, explaining the narrow profitability.
Management's 2026 priorities emphasize business model optimization through sales performance plan enhancements, Prysm iO intelligent wellness platform rollout following Q1 leader previews, and India expansion. These initiatives explain G&A investments despite revenue challenges. Cash flows are expected sufficient for ongoing quarterly dividends, with no material tax impact anticipated from OBBBA. Risks persist from macro pressures, tariff uncertainty delaying orders, and execution needs to stabilize sales leader trends.